{"id":43617,"date":"2023-11-20T03:41:36","date_gmt":"2023-11-20T09:41:36","guid":{"rendered":"https:\/\/stage.cancerimagingarchive.net\/tcia-citation\/a091105-pub\/"},"modified":"2023-11-20T03:41:36","modified_gmt":"2023-11-20T09:41:36","slug":"a091105-pub","status":"publish","type":"tcia_citation","link":"https:\/\/stage.cancerimagingarchive.net\/tcia-citation\/a091105-pub\/","title":{"rendered":"A091105-PUB"},"template":"","class_list":["post-43617","tcia_citation","type-tcia_citation","status-publish"],"tcia_citation_type":"Publication Citation","tcia_citation_text":"<p><span><span>Gounder, M. M., Mahoney, M. R., Van Tine, B. A., Ravi, V., Attia, S., Deshpande, H. A., Gupta, A. A., Milhem, M. M., Conry, R. M., Movva, S., Pishvaian, M. J., Riedel, R. F., Sabagh, T., Tap, W. D., Horvat, N., Basch, E., Schwartz, L. H., Maki, R. G., Agaram, N. P., \u2026 Schwartz, G. K. (2018). Sorafenib for Advanced and Refractory Desmoid Tumors. In New England Journal of Medicine (Vol. 379, Issue 25, pp. 2417\u20132428). Massachusetts Medical Society<\/span>. <a href=\"https:\/\/doi.org\/10.1056\/nejmoa1805052\">https:\/\/doi.org\/10.1056\/nejmoa1805052<\/a><\/span><\/p>\n","tcia_citation_statement":"","tcia_citation_doi":"10.1056\/nejmoa1805052","_links":{"self":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/v1\/citations\/43617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/v1\/citations"}],"about":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/wp\/v2\/types\/tcia_citation"}],"wp:attachment":[{"href":"https:\/\/stage.cancerimagingarchive.net\/api\/wp\/v2\/media?parent=43617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}